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7AbstrAct
It is common that critically ill patients develop muscle weakness in the intensive care unit (ICU), 
not only delaying mobilisation and increasing the risk of co-morbidities, but also prolonging 
rehabilitation after hospital care. The aim of this thesis was to describe the diagnosis, time course 
and possible risk factors for this weakness.
When specific diseases such as CNS lesions, intoxication or other nerve and muscle disorders have 
been excluded in the ICU, a ”critical  illness polyneuropathy and myopathy” (CIPNM) should be 
considered. The pathology behind this entity is unclear; among possible etiologic factors sepsis, 
corticosteroids and neuromuscular blocking agents (NMBAs) have been suggested.
CIPNM consists of a nerve pathology (neuropathy) and/or a muscle pathology (myopathy) and 
is diagnosed by a clinical assessment in combination with neurophysiological examination. The 
latter can be cumbersome due to the challenging environment in the ICU and is in itself not a 
definitive method of differentiating between a polyneuropathy and a myopathy.
We demonstrate a rapid method of electrophoresis, using an ultra-thin gel to evaluate the myosin 
to actin (M/A) ratio as a means of diagnosing critical illness myopathy (CIM). Using this 
diagnostic tool, there was a significant difference in M/A ratio between the patients having CIM, 
a control group, and patients having axonal neuropathies.
To evaluate the prevalence of CIPNM and the temporal pattern of its two major components critical 
illness polyneuropathy (CIP) and CIM, a prospective study was conducted including ICU patients 
who had been mechanically ventilated for at least 72 hours. The eventual prevalence of CIPNM 
was investigated, including neurophysiological and clinical examination. Muscle biopsies were 
obtained, in order to study the myosin to actin ratio and mitochondrial function. All septic patients, 
who were also receiving corticosteroid treatment, had a CIPNM diagnosis, whereas none of the 
non-septic patients fulfilled the necessary criteria. As a marker of oxidative stress, mitochondrial 
superoxide dismutase was increased in all patients, with a marked elevation in the CIPNM group. 
To examine possible predisposing risk factors and mechanisms behind CIPNM in an experimental 
porcine ICU model over 5 days, groups were separated by interventions including corticosteroids, 
neuromuscular blocking agents and endotoxin, during mechanical ventilation. No group had a 
pathologic M/A ratio. All groups had significant changes in compound muscle action potential 
amplitude, including the inactivity/mechanical ventilation only group. The groups including 
corticosteroid treatment, endotoxin and the combination of all interventions had decreased muscle 
specific force and mitochondrial complex I activity, which were not seen in the mechanical 
ventilation group. 
In conclusion, this thesis demonstrates an alternative method of diagnosing a critical illness 
myopathy, which could prove to be both time-efficient and reliable. In ICU patients there was 
a high prevalence of CIPNM in patients mechanically ventilated for more than 72 hours. An 
experimental model showed both decreased specific muscle force and mitochondrial complex 
I activity in intervention groups receiving corticosteroids, endotoxin or a combination, for both 
respiratory and non-respiratory muscles.
Key words: myopathy, polyneuropathy, critical illness, myosin to actin ratio, single muscle fibre 
force, mitochondrial dysfunction
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AbbreviAtions
ACh Acetylcholine
ADP Adenosine diphosphate
APACHE Acute Physiology and Chronic Health Evaluation
ARDS Acute Respiratory Distress Syndrome
ATP Adenosine triphosphate
AQM Acute Quadriplegic Myopathy
CIM Critical Illness Myopathy
CIP Critical Illness Polyneuropathy
CIPNM Critical Illness Polyneuropathy and Myopathy
CMAP Compound Muscle Action Potential
CNS Central Nervous System
CoS Corticosteroids (paper IV)
CP Creatine phosphate
CS Citrate synthase (paper IV), corticosteroids (paper III)
CSA Cross Sectional Area
CV Conduction Velocity
dl Decilitre
EMG Electromyography
ENeG Electroneurography
ICU Intensive Care Unit
LPS Lipoprotein Polysaccharide
min Minute
ml Millilitre
mSOD Mitochondrial Superoxide Dismutase
MyHC, MHC Myosin Heavy Chains
NADH Nicotinamide Adenine Dinucleotide
nm Nanometre, 1x10-9 m
NMBA Neuromuscular Blocking Agent
PaCO2 Arterial carbon dioxide tension
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
SIRS Systemic Inflammatory Response Syndrome
SNAP Sensory Nerve Action Potential
SR Sarcoplasmic Reticulum
TG Triglycerides
TnC Troponin C
TnI Troponin I
TnT Troponin T
WBC White Blood Cell
All images printed with permission of the respective copyright owner.
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introduction
Background
Early in my career as specialist in anaesthesia 
and intensive care medicine, I was intrigued 
by the fact that some patients in the Intensive 
Care Unit (ICU) were apparently awake and in 
some cases could only communicate with the 
help of their facial muscles, but were otherwise 
completely or partially paralysed. When trying 
to find diagnostic guidance for these patients 
in addition to regular bedside evaluation, 
there often seemed to be a practical problem, 
with neurophysiological examinations taking 
both time and space in the equipment-filled 
area around the ICU patient. At that time, 
corticosteroids were used in sepsis and other 
disease states in the ICU, and although rarely 
used in Sweden, neuromuscular blocking agents 
were often a part of regular ICU treatment in 
other parts of the world. Both these classes 
of agent were suspected of being part of the 
problem1-3, but without a clear understanding 
of the mechanism(s) involved, it seemed 
attractive to use an established animal ICU 
model in order to examine these issues and 
agents. 
It was brought to my attention during 
discussions with physiotherapists and 
occupational therapists at the hospital that 
the problem with skeletal muscular weakness 
involved not only the period of ICU care, but 
rather the whole period of in-hospital care after 
the initial period of critical illness. Indeed, 
several studies have focused on this issue, 
showing prolonged periods of neuromuscular 
dysfunction after hospital discharge with a need 
for rehabilitation, which clearly consumes both 
time and money. My thesis is based on these 
reflections.
The muscle 
Muscle is classified into three subtypes: 
skeletal, smooth and cardiac. Skeletal muscle is 
voluntary and striated, cardiac muscle is striated 
and involuntary while smooth muscle (internal 
organ walls, blood vessels) is non-striated and 
involuntary.  This thesis exclusively involves 
skeletal muscle.
Skeletal muscle can be categorised by means of 
physiology, biochemistry and histochemistry. 
Different subtypes of muscle fibres have been 
described when combining these techniques. 
Human muscle fibres usually are classified 
into three categories based on ATPase staining 
– type I, IIA and IIB. Using other techniques 
like electrophoresis show additional myosin 
isoforms. Some mammals, like pig, exhibit 
an intermediate form, MHCIIb, not seen in 
humans 4, 5 (table 1).
Skeletal muscle not only serves as support 
for body posture and a force generator. For 
instance, some interleukins - IL-6, IL-8 and 
IL-15 – are produced, expressed and released 
in muscle fibres, and have been termed 
myokines, together with other peptides that 
possess the same characteristics 6. IL-6 is 
considered a pro-inflammatory cytokine but 
has anti-inflammatory properties as well 7. It 
is released during muscle exercise and may 
protect against insulin resistance8. IL-8 is also 
induced by exercise, and may be involved in 
angiogenesis 9 and seems to exert its effect 
locally in the muscle10. IL-15 is suggested being 
a factor involved in muscle growth11  and also 
in the interaction between muscle and adipose 
tissue12.  Although these cytokines are not evaluated within this thesis, it certainly is 
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Skeletal muscle is formed by cylinder-shaped 
units containing fibres made of actin and 
myosin, giving the muscle its characteristic 
striated appearance (figure 1).
Actin (”thin filament”) is an important 
component in the cytoskeleton, where it 
gives mechanical support to the cell and 
also promotes signal transduction. Together 
with troponin and tropomyosin it forms thin 
filaments in skeletal muscle. Troponin (Tn) 
Figure 1. Schematic drawing of the muscle fibre. From Cooper: The Cell: A Molecular 
Approach, Second Edition, Sinauer Associates, Inc., Sunderland MA, USA, 2000 
Table 1. Adult skeletal muscle myosin heavy chain (MHC) isoforms and their characteristics
Fibre type (mATPase) Type I Type IIA Type IIB Not in humans
MHC isoform MHCI MHCIIa MHCIIx MHCIIb
Contraction time slow medium fast fast very fast
Motor neuron size small medium large very large
Fatigue resistance high intermediate intermediate low
Activity aerobic long term anaerobic 
short term 
anaerobic
short term 
anaerobic
Force production low medium high high very high
Mitochondrial density high high medium low
Capillary density high medium low low
Oxidative capacity high high medium low
Glycolytic capacity low high high high
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consists of three subunits: TnT which interacts 
with tropomyosin; TnC binds calcium and TnI 
binds to actin.
In relaxed muscle, tropomyosin situated on 
actin filaments blocks sites that bind myosin. 
 
Myosin (”thick filament”) is a motor protein 
which accounts for approximately 50% of 
total muscle protein and is dependent on ATP 
for its function. It moves along actin while 
hydrolysing ATP. There are at least 30 different 
genes encoding for myosin in the human 
genome; there are certainly many other, non-
muscular functions which are not yet fully 
known 13. 
Myosin and actin form a contractile complex, 
also called actomyosin, in skeletal muscle. The 
myosin class II – the actomyosin component 
in human skeletal muscle -  was the first to be 
discovered, and up to date there are 35 known 
classes  in eukaryotes14.The ratio between 
myosin and actin has been shown to be a good 
marker of critical illness myopathy 15-16.
The muscle contraction (figure 2)
In brief, a skeletal muscle contraction starts 
with either conscious brain-initiated or reflex-
initiated spinal cord activity. An electrical action 
potential propagates along the myelinated 
nerve axon and finally arrives at the nerve 
ending which forms the so-called motor end 
plate on a number of muscle fibres. One axon 
can connect to several muscle fibres, but each 
muscle fibre only has one axon connected to it. 
Triggered by the arrival of an action potential, 
acetylcholine (ACh) is released from the nerve 
ending into the synaptic cleft. Typically, this 
massive release of ACh results in activation of 
pre- and postsynaptic ACh receptors, causing 
a net influx of cations that ultimately changes 
the resting potential under the motor end plate. 
This change in end plate potential initiates a 
muscle action potential that spreads inside the 
muscle fibre through its T-tubules, and releases 
calcium from the sarcoplasmic reticulum 
(SR). Calcium binds to TnC which moves 
tropomyosin, allowing myosin to bind, and the 
muscle contracts. By cleaving ATP to ADP + 
phosphate, myosin produces mechanical force. 
When a new ATP molecule binds on the myosin 
head the actin/myosin bond is released and the 
muscle relaxes. Calcium is transported back to 
Figure 2. Schematic drawing of the muscle contraction. Adapted from The muscle cell, J.C Sloper et al, J. Clin Pathol.Suppl. (Roy Coll. Path.), 1978;12, 25-43
Introduction
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the SR. For a more complete description, see 
Huxley 17. 
The motor unit 
A motor unit is a single nerve and the corre-
sponding muscle fibres it supplies. The size 
of a motor unit depends on which type of 
muscle is involved; i.e. a muscle involved 
in very precise movements has fewer mo-
tor fibres per nerve fibre than a large mus-
cle, like the quadriceps femoris. The more 
pronounced the muscle contraction, the 
more and larger motor units are recruited 18. 
In a nerve injury (neuropathy), the connection 
beween the nerve and muscle fibres is initially 
lost. This results in fewer working motor units 
being activated in a muscle contraction, called 
”reduced recruitment”. If, on the other hand, 
the muscle fibre itself is damaged (myopathy), 
the number of motor units is unaffected, but 
the generated force is lower than normal. To 
compensate for this, more motor units are fired 
at the same time to achieve the desired mus-
cle force. This phenomenon is called ”early 
recruitment”. The force generated depends on 
how many motor units are activated, and the 
frequency with which they are activated.
Neurophysiology in clinical 
use
Neurophysiological investigations are used to 
assess neuromuscular function, e.g.  when a 
patient in the intensive care unit (ICU) presents 
with muscular weakness without obvious 
cause. In addition to a clinical evaluation by a 
neurologist, a neurophysiological examination 
most often including electroneurography 
(ENeG) and electromyography (EMG) is 
performed. Together, these investigations 
usually can determine if there is an isolated, 
or combined, pathology in the nervous 
system; in the muscle, peripheral nerve, or the 
neuromuscular junction. 
ENeG includes the investigation of nerve 
conduction velocity (CV), calculated from the 
time from a nerve stimulation to a compound 
muscle action potential (CMAP), or a sensory 
nerve action potential (SNAP) generation. 
This velocity is dependent on the diameter 
of the nerve fibre (the larger the faster) and 
if it is myelinated or not. A myelinated nerve 
fibre generally has a higher CV than an 
unmyelinated nerve fibre. In general, in an 
axonal degeneration disorder, CV is normal or 
near normal; in a demyelinating disease like 
demyelinating forms of the Guillain-Barré 
syndrome, the CV is decreased. 
CMAP is the sum of the response of action 
potentials from the muscle fibres when the 
supplying motor nerve is stimulated. This 
amplitude is dependent on the number of axons 
stimulated, the neuromuscular transmission, 
and the size of the muscle fibres. CMAP is 
decreased in a myopathy and in an axonal 
degeneration disorder, but is usually normal 
or near normal in pure demyelinating diseases. 
The SNAP is recorded from superficial, sensory 
nerves. The SNAP is normal in pure motor 
disorders such as spinal muscular atrophy, 
whereas it is usually low or absent in sensory 
and sensorimotor polyneuropathies. 
EMG can be conducted with either surface 
electrodes or a needle. Needle EMG is used 
clinically in the evaluation of a neuropathy 
or myopathy, since it provides detailed 
configuration information of the motor unit. In 
contrast, surface EMG is a quantitative method, 
giving little or no information of the motor unit 
complex.
The EMG needle can be of single-fibre type 
(recording of a single muscle fibre), concentric 
(recording of approximately 2-15 fibres at a 
time), or a macro-EMG (recording of an entire 
motor unit). Denervation activity, recruitment 
pattern and the configuration of the motor unit 
– amplitude, duration, area and complexity – 
can be investigated and is generally useful in 
differentiating  between a neuropathy and a 
myopathy. Also, a differentiation between acute 
and chronic conditions can be distinguished 
with EMG19.
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Muscle weakness in the 
Intensive Care Unit
The history of specialised intensive care units 
(ICUs) started in 1953 when the first ICU 
was established in Copenhagen during a polio 
epidemic 20. Patients in need of treatment and 
care in such units have frequently been referred 
to as being critically ill. More precisely, the 
term “critically ill”, meaning a condition 
which acutely impairs one or more vital organ 
systems, such that there is a high probability 
of imminent or life-threatening deterioration 
in the patient’s condition, was initially coined 
for ICU patients. Notably, improved care on 
regular wards and high demand for ICU care 
may nowadays render quite ill patients being 
treated outside the ICU on other hospital wards. 
Therefore it is important to remember that the 
muscular weakness described within this thesis 
is relevant not only for ICU patients, but rather 
for all patients suffering from multiple organ 
failure, regardless of the hospital location in 
which their care is provided.
Although new, specific ICU treatments might 
be causative, muscle weakness during intensive 
care has most probably always affected criti-
cally ill patients, but has generated increasing 
interest due to improved survival rates, leading 
to a focus on post-ICU outcomes and problems 
- including neuromuscular sequelae which had 
previously gone undetected.
A large proportion of ICU patients may either 
have sepsis on arrival, or will later develop 
sepsis during the intensive care period 21. 
According to the definition proposed by Bone 
et al 22, sepsis ”represents the systematic 
inflammatory response to the presence of 
infection”. Importantly, this response is often 
associated with neuromuscular sequelae. 
Within this thesis, stated sepsis in the studies 
means a SIRS caused by a confirmed infection. 
The SIRS definition is stated in table 1.
Underlying disease and/or the treatment 
involved rendering the patient immobilised by 
muscular weakness is a well-known sequela of 
intensive care. When a patient exhibits clinical 
signs of muscular weakness, and other possible 
causes have been excluded (for differential 
diagnoses see Table 2), an intensive care-
acquired weakness should be considered. 
SIRS (systemic inflammatory response syndrome) 
as manifested by two or more of the following conditions:
Temperature       >38o or <36o Celsius
Heart rate           > 90 beats . min-1
Respiration rate  > 20 breaths . min-1 or PaCO2 < 4.2 kPa 
WBC                   >12 or <4 x 103 . ml -1 or > 10% immature (band) forms
Table 1. SIRS definition.
Causes of muscular weakness in the ICU
Residual ICU drug effect
Intoxication
Guillain-Barré syndrome
Myasthenia gravis
CNS injury/lesion
Spinal cord injury
Table 2. ICU weakness: differential diagnoses.
Pre-existing peripheral nerve disorders
Pre-existing muscle disorders
Significant electrolyte imbalance
Disorders of the neuromuscular junction
Psychiatric disorders
Introduction
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Critical Illness Polyneuropathy 
and Myopathy (CIPNM) 
Initially brought to our attention by two fre-
quently cited case reports some 30 years 
ago 23-24, muscle weakness in the critically 
ill acquired during intensive care was later 
found to be both common and sometimes se-
vere25-27. Steroids and neuromuscular block-
ing agents were soon considered to be pos-
sible pharmacological etiologies, but results 
in this area have been inconclusive 28-29. 
A patient with muscular weakness, e.g. evalu-
ated by using a motor sum score 30 (table 3), and 
by evidence of polyneuropathy and/or myo- 
pathy, is by definition suffering from CIPNM if 
the causes in table 2 have been excluded. 
Nomenclature has been diverse for this condi-
tion, sometimes describing a pure myopathy 
or a polyneuropathy, and sometimes being 
a heterogeneous term describing the occur-
rence of one or both 31-36 exemplified below: 
CIPNM was coined by deLetter et al in 2000 37,
a term which includes a muscle weakness 
consisting of a polyneuropathy and/or a 
myopathy. Previous studies have described 
the occurrence of CIPNM, which is important, 
but have not shown the temporal changes in 
CIPNM during the course of intensive care.
Polyneuropathy (PNP) and myopathy 
(MP) diagnosis 
Critical illness polyneuropathy (CIP), usually 
has both an axonal motor and a sensory origin. 
The motor deficit might be revealed by difficul-
ties in weaning from mechanical ventilation, 
in physiotherapy mobilization 38, or by respi-
ratory weakness forcing a patient from non-
invasive ventilation to becoming mechanically 
ventilated (e.g. phrenic nerve neuropathy). 
There is no agreement upon an exact defini-
tion of a PNP, although clinical recommenda-
tions exist 39. The following are usually con-
sidered diagnostic: a) a significant decrease in 
CMAP and/or SNAP amplitudes b) a normal, 
or near normal, nerve conduction velocity (in 
axonal forms; in the case of a demyelinating 
disease, CV is significantly decreased) c) a 
typical EMG pattern including reduced recruit-
ment and possibly also spontaneous activity d) 
a predominantly distal muscular weakness, 
and/or distal sensory changes. A myopathy is 
most often diagnosed by muscular weakness, 
normal SNAP amplitudes, and myopathy-
specific EMG findings such as short-dura-
tion, small-amplitude motor unit potentials 
with early recruitment. It is important to re-
member that voluntary effort by the patient 
often is required to make a diagnostic EMG. 
Critical illness myopathy Intensive Care Unit Acquired Weakness (ICUAW)
Thick filament myopathy Critical Illness neuromuscular abnormalities
Acute quadriplegic myopathy ICU-acquired paresis
Acute necrotising myopathy Critical Illness neuromyopathy
Acute corticosteroid myopathy Critical Illness neuromuscular syndromes
Critical Illness Polyneuropathy and 
Myopathy (CIPNM) Critical Illness myopathy and neuropathy (CRIMYNE)
Table 4. Examples of terms for intensive care-acquired weakness. 
Medical Research Council Scale for 
assessment of muscle power
0 No movement
1 Perceptible muscle flicker
2 Movement if gravity is eliminated
3 Can move limb against gravity
4 Some examiner resistance
5 Normal power
Table 3. MRC muscle power scale.
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CIPNM is thus a heterogeneous diagnosis, in-
cluding either, or both, a polyneuropathy and a 
myopathy, which presents with a clinically re-
duced ability to contract muscles on command 
or to painful stimuli, usually located to distal, 
lower limbs. Facial muscle weakness in this 
condition is rare40. Because it can be difficult 
to differentiate between CIP and CIM 41, the 
term CIPNM has often been used.
Investigation of these entities can be cumber-
some, due to the limitations which result from 
patients being confined to the ICU. Both the 
space available for additional equipment and 
undisturbed time for examination can be limit-
ed. We therefore wanted to present an efficient 
method as an additional tool for diagnosing 
CIM as an alternative to today’s methods. 
Based on the above, ICU-acquired muscular 
weakness is either a myopathy, a polyneuro-
pathy or a combination of both. In this thesis, 
the confirmed diagnosis by neurophysiology 
and clinical examination is called CIPNM (pa-
per II). In paper I and III the focus is on my-
opathy and therefore the term CIM or AQM is 
used. The term ”muscular weakness” is a more 
general description of the muscular condition 
of the patient at the ICU. 
 
Many mechanisms have been suggested for 
the development of CIPNM 42-48. These include 
pathophysiological alterations in muscle and 
nerve axon circulation leading to local nerve/
muscle ischemia, as typically seen in situations 
of circulatory instability, including sepsis-
induced pro-inflammatory effects on nerve and 
muscle tissue with oedema and local hypoxia 25. 
Other mechanisms involving metabolic 
derangement such as hyperglycemia, prolonged 
disuse and direct toxic pharmacological effects 
of medication used to treat the critically ill, 
have been suggested. Hence, by the time this 
thesis was launched, there was a controversy 
regarding the role of immobilisation and the 
systemic administration of corticosteroids and/
or NMBAs in the development of CIPNM. 
We believe there are reasons to suggest that 
corticosteroids, without or in combination 
with prolonged pharmacological paralysis, 
play a key role. Based on previous findings in 
the ICU patient 49-50 we also wanted to explain 
whether there was an association between 
skeletal muscle mitochondrial dysfunction and 
skeletal muscle weakness in critical illness.
Immobilisation
Separating the effects of bed rest in the ICU 
from the effects of disease and pharmacological 
effects of medication on the muscle function 
is not feasible. After discharge from hospital, 
many patients with CIPNM still report muscle 
weakness up to years after hospitalisation 
and objective tests confirm this weakness44,51. 
Experimental inactivity models show that 
muscle mass decreases by around 2% daily 
the first two to three weeks of inactivity, which 
mainly is due to decreased muscle fibre size 
including the loss of contractile proteins52. 
Also, early in the immobilisation phase, an 
upregulation of ACh receptors takes place53.
Corticosteroids 
The use of steroids in the ICU has been debated 
for decades, balancing positive effects during 
sepsis, airway oedema, and autoimmune 
disorders against effects such as increased rates 
of infection, duration of ventilator support and 
ICU stay 54. 
Several mechanisms for the pathogenesis 
responsible for CIPNM development have 
been suggested; for instance, activation of the 
ubiquitin-proteasome pathway, reduced IGF-
effects and apoptosis 55. In an animal model, 
corticosteroid administration led to changes 
similar to critical illness myopathy; changes 
also worsened with limb denervation before 
administration 56. Chronic use of corticosteroids 
can result in a myopathy, clinically seen as 
a muscle weakness and an atrophy, which 
primarily affects type II fibres. The mechanisms 
behind this are not fully clarified, but decreased 
protein synthesis, increased myofibrillar 
proteolysis and apoptosis induction have been 
suggested57.
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Neuromuscular blocking agents 
(NMBAs) 
As ICU care trends toward lighter sedation and 
earlier mobilisation, the use of NMBAs has 
decreased in many ICUs. Nonetheless, reports 
show that almost 15% of patients in the ICU 
receive NMBAs for at least one day, which is 
associated with a longer stay in the ICU and 
higher mortality 58, and in two recent ARDS 
studies a large proportion of the patients were 
treated with NMBAs 59-60. In contrast to the 
proposed deleterious effects on neuromuscular 
function, there are also results which suggest 
that NMBAs specifically increase survival and 
decrease time on the ventilator in these patients61. 
Apart from effects on neuromuscular 
transmission and cholinergic signalling62, 
pharmacological denervation per se is a 
mechanism by which NMBAs most likely 
contribute to CIPNM development, but 
changes in muscle plasma proteins have also 
been suggested 63. 
The mitochondrion 
Mitochondria (figure 3) are considered the 
”power plant” of the cell, providing energy. 
Like the nucleus, the mitochondrion has a 
double membrane composed of proteins and 
phospholipids. The outer membrane is smooth, 
and allows the passage of nutrients, ATP, ADP 
and different ions. The inner membrane is 
only permeable to oxygen, carbon dioxide and 
water, but contains transport proteins which 
carry compounds across the membrane64. 
It is convoluted into folds called cristae, 
which greatly increase the surface area. On 
these cristae, enzymes and electron carriers 
(cytochromes) responsible for yielding 
energy from glucose are housed (figure 4). 
The enzyme complexes are usually named 
by roman numerals I-V (table 5). The two 
compartments formed by the membranes are 
the intermembrane space, which is important 
for oxidative phosphorylation, and the matrix, 
which contains hundreds of enzymes and 
mitochondrial DNA.
Mitochondrial dysfunction is involved in 
a large and increasing number of known 
diseases, including several that affect muscle, 
such as Kearns-Sayres syndrome, MELAS 
(mitochondrial encephalomyopathy with 
lactate acidosis and stroke-like episodes), and 
MNGIE (mitochondrial neurogastrointestinal 
encephalomyopathy). Changes in mito-
chondrial function have been observed in 
sepsis65. Muscular weakness is a known 
sequela of sepsis in the ICU, and there are some 
novel approaches to examining the specific 
mitochondrial changes in regard to muscular 
dysfunction in the ICU49-50. 
As already mentioned, corticosteroid and 
NMBA treatment are thought to contribute to 
this muscular weakness, and specific research 
on mitochondrial function in regard to these 
interventions has to my knowledge not been 
done before.
Complex I NADH dehydrogenase
Complex II Succinate-coQ-reductase
Complex III CoQ-cytochrome c reductase
Complex IV Cytochrome oxidase
Complex V ATPsynthase
Table 5. Mitochondrial enzyme complexes. CoQ: coenzyme Q.
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Figure 4. Schematic drawing 
of the respiratory chain in 
the mitochondrion. Courtesy 
of Fvasconcellos, Wikimedia 
commons.
Figure 3. The mitochondrion  as 
a) a schematic drawing, and 
b) in a transmission electron micrograph. 
From Johnson, Losos: Living World, 5ed 
2008. McGraw-Hill Education, NY, USA
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Clinical and experimental studies
It is generally accepted that clinical studies in 
septic patients must often overcome multiple 
difficulties.66.  As the ICU population is very 
heterogeneous, the challenge of separating 
and accounting for different factors, such as 
underlying disease and ICU complications 
(e.g. infection and administration of numerous 
different groups of medications) in a prospective 
study can be insurmountable. Animal models 
designed to account for various individual 
variables are therefore often used. Because 
there is a lack of ICU animal models of longer 
duration than a few days, we developed a 
5-day porcine sepsis model 67 which combines 
pharmacological interventions with variables 
such as immobilisation and sepsis, that are 
suspected to have a causative role.
25
Aims
The overall aim of this thesis was to evaluate muscle function in the critically ill, with 
reference to the muscular weakness acquired in the intensive care unit.
The specific aims were: 
I. To develop and evaluate a rapid method of quantifying myosin in patients with criti-
cal illness myopathy 
II. To describe the time course of changes in muscle and nerve neurophysiology, histo-
logy and mitochondrial function in critically ill patients requiring mechanical ventila-
tion 
III. To explore the relative importance of immobilisation during mechanical ventilation, 
endotoxemia, and treatment with neuromuscular blocking agents and corticosteroids, 
on intensive care-acquired muscular weakness, using a five day porcine intensive care 
model 
IV. To investigate the effect of immobilisation during mechanical ventilation, and of 
combinations of endotoxemia and pharmacological interventions on muscle function, 
as assessed by mitochondrial enzyme changes in a five-day porcine intensive care  
model. 
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between Yorkshire and Swedish Landrace, en-
tered this 5-day experimental study. They ori-
ginated from the same farm and had free access 
to food, water and environmental enrichment 
before entering the study. Food, but not water, 
was withheld for 12 hours before scheduled 
anaesthesia. Two piglets died before the study 
protocol was finished, and in another two pig-
lets the unexpected low quality of muscle spe-
cimen did not allow them to be included in the 
single muscle fibre examination. Therefore, 
18 animals remained available for this study. 
Paper IV  
The same animals as in paper III were used for 
muscle mitochondrial analyses. The two piglets 
unsuitable for single-fibre analyses, and the 
two that did not survive for neurophysiological 
examinations in paper III but could be used 
for muscle biopsy, were analysed in this paper. 
Four sham surgery animals were also included, 
since muscle biopsies from the diaphragm and 
intercostal muscles could not otherwise be 
obtained before day 5, i.e. the last study day. 
 
Neurophysiological 
examination (papers I-III) 
In paper I and II, EMGs in the distal and proxi-
mal muscles of the upper and lower extremi-
ties, and ENeGs including the upper (median/
ulnar nerves) and lower (peroneal/tibial/sural 
nerves) extremities were performed on all en-
rolled patients, including measurements of 
motor and sensory CVs, CMAPs and SNAPs, 
according to the standard clinical polyneuropa-
thy protocol at the Neurophysiology Labora-
tory of the Karolinska University Hospital. 
mAteriAL And methods
Patients
Paper I  
Eleven patients, who all developed multiple 
organ failure in an intensive care unit at the 
Karolinska University Hospital, were enrol-
led. During the course of routine intensive 
care, the patients exhibited clinical signs of 
muscular weakness, and after a neurophysiolo-
gical examination, consultation by a neurolo-
gist and a histological examination of muscle 
biopsies, either a pure CIM or a combination 
with a neuropathy was diagnosed. 42 controls 
had muscle biopsies taken as part of a routi-
ne investigation for various muscular symp-
toms. Twelve of these were considered heal-
thy. In addition, five patients with an axonal 
neuropathy were included to study the effect 
of axonal injury upon the myosin/actin ratio. 
Paper II 
Ten patients admitted to one of the adult 
intensive care units at the Karolinska Uni-
versity Hospital were enrolled after approval 
by next-of-kin. Inclusion criteria were an age 
between 18-80 years and mechanical ventila-
tion for at least 72 hours, plus the absence of 
a) any previous neuromuscular disorder; b) 
the use of neurotoxic drugs; and c) any condi-
tion precluding a muscle sample being taken. 
If participation of both the including ICU and 
neurophysiology physician was assured for all 
investigational days (4,14 and 28), the patient 
was included. 
Animals 
Paper III 
22 female piglets, of a commercial crossbreed 
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In paper III, the electroneurography (ENeG) 
analysis included peroneal motor nerve con-
duction velocities on days 1 and 5 of the ex-
periment. The tibialis anterior muscle com-
pound muscle action potential (CMAP) am-
plitudes were recorded upon supramaximal 
stimulation of the motor nerve. The EMG 
analysis included bilateral concentric needle 
EMG examination of proximal hind limb. 
 
Muscle biopsy examination 
(papers I-IV) 
Muscle biopsies from the tibial anterior (paper 
I),  vastus lateralis (papers I+II) or the biceps 
femoris (paper III+IV) muscles were obtained 
under local anaesthesia. Cross sections were 
stained as per standard methods 68. SDS-PAGE 
electrophoresis was carried out on homog-
enised and centrifuged muscle specimens and 
the gels were scanned to determine the myosin 
to actin ratio (papers I-III).
Mitochondrial analyses on citrate synthase, 
complexes I, IV and mSOD were performed 
using spectrophotometric assays, after homog-
enisation and centrifugation49 (papers II+IV) 
Single muscle fibre analyses regarding spe-
cific force and shortening velocity were 
conducted. MHC isoform expression was 
also performed (paper III). For more spe-
cific information, see Ochala et al 69 
 
Interventions (papers III+IV) 
 
All animals were mechanically normoventilat-
ed using volume controlled ventilation using a 
Siemens 900A ventilator (Siemens-Elema, Sol-
na, Sweden) at arterial normoxemia and nor-
mocapnemia. Arterial and central venous cath-
eters, including a Swan-Ganz thermodilution 
pulmonary artery catheter, were positioned via 
the carotid artery and internal jugular vein, re-
spectively. Continuous intravenous infusion of 
Ringer’s acetate and glucose were administered 
to carefully maintain normoglycemia, because 
enteral feeding was not considered practical, and 
additional parenteral nutrition has been shown 
to result in fat vacuolisation in muscle cells 15. 
Including a pure mechanical ventilation group, 
the animals were divided into different inter-
vention groups: sepsis, NMBA, CS (corticos-
teroid) and ALL (all interventions combined). 
 
Sepsis (endotoxin) and ALL groups 
The group named ”sepsis” in paper III is 
called ”endotoxin” in paper IV, in order 
to reflect intervention rather than result. 
10 ug LPS/kg (Sigma Chemical, St. Louis, 
Missouri, USA) was diluted in 20ml sodium 
chloride to 0.5 ug . kg-1 . ml-1. The infusion was 
started at 2 ml . h-1(1ug . kg-1 . h-1) and titrated 
until a hemodynamic response occurred, con-
sisting of a fall in arterial mean blood pressure 
>30% from baseline, with an increase of >50% 
in pulmonary artery systolic pressure from 
baseline. The infusion was paused if the ani-
mals required fluid resuscitation or administra-
tion of adrenalin for bradycardia, and was then 
restarted at a lower dose. If the animal required 
repeated interventions the infusion could be 
terminated earlier than one hour, and if toler-
ated could run for up to four hours.
NMBA group (and ALL group)
An intravenous infusion of 25 mg/hour of 
rocuronium (Esmeron, Schering-Plough AB, 
Stockholm, Sweden) was administered over 
the whole experimental period.  If a return 
of spontaneous movement was observed, the 
animals received additional bolus doses of 
rocuronium of 10-20 mg. 
 
Corticosteroid group (and ALL group) 
Animals received 50 mg of hydrocortisone 
(Solu-Cortef, Pfizer AB, Sollentuna, Sweden) 
intravenously every 8 hours throughout the 
experimental period.
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resuLts
Paper I
Histological and neurophysiological changes
Using a light microscope, pathological 
changes were observed in all biopsies (table 
6). These included fibre atrophy (figure 5), de/
regeneration, necrosis and rounded enlarged 
nuclei which were centralised or in the 
subsarcolemmal regions (figure 6). Preferential 
loss of thick filaments was observed in 
electron-microscope evaluation. There was 
no relationship between the degree of change, 
age and APACHE II score or time of biopsy. 
Neurophysiological data showed that motor 
nerve CV was normal and CMAP decreased 
for all patients.  
Method evaluation and myosin to actin ratio
Sample dilution of 1:2 yielded the best results, 
compared to 1:5 dilution and undiluted 
specimen. The within-gel variation was 4%. 
Dried or stored gel increased the M/A ratio. 
All patients with confirmed CIM had a mean 
M/A ratio of 0.37±0.17, while the mean value 
for controls was 1.37±0.21. A group with 
axonal neuropathies had a mean M/A ratio of 
1.57±0.19.
Patient M/A Age Nuclear changes Regeneration ATPase loss Fibre atrophy
1 0.37 54 + + + +
2 0.17 76 ++ + + ++
3 0.22 61 ++ + + +
4 0.31 63 +++ + + ++
5 0.69 68 +++ +++ +++ +++
6 0.63 36 ++ + + +
7 0.26 65 + + + +++
8 0.28 59 +++ +++ +++ +++
9 0.37 57 +++ +++ +++ +++
10 0.31 61 +++ +++ +++ +++
11 0.43 16 ++ + + +
Table 6. Histopathological changes and myosin to actin ratio (M/A). 
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Figure 5. A muscle specimen from a patient with very mild histological changes.
Figure 6. Severely affected muscle with obvious myopathic changes, including enlarged 
rounded nuclei.
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Paper II
Apart from a single dose of succinylcholine be-
fore  intubation, and a single dose of atracurium 
at day 15 for one patient, no NMBAs were given. 
All (5/10) septic patients received cortico-ster-
oids (hydrocortisone 50-100mg three times 
daily for 5-10 days) and all fulfilled criteria 
for CIPNM. No non-septic patients fulfilled 
CIPNM criteria, including one with ongoing 
corticosteroid treatment for chronic obstruc-
tive pulmonary disease. Three patients had a 
M/A ratio <1.0, and all three were admitted 
to the ICU because of sepsis.  The temporal 
changes are seen in table 7. Overall, septic pa-
tients showed more CMAP and SNAP pathol-
ogy than non-septic patients (table 8).
Muscle biopsies and mitochondrial analyses
Discrete light microscopic changes were seen on 
day 14 for all but one patient.  Citrate synthase 
decreased by 37% and mSOD increased by 61% 
in the whole group; for the septic patients mSOD 
increased by 116%. No significant changes 
were seen in mitochondrial complexes I and IV.  
Day 4 Day 14 Day 28
M/A < 1.0 0 3 n/a
CIP 5 3 2
CIM 0 2 1
CIPNM 5 5 2
Patients in the ICU 10 5 2
Mobilised patients 0 4 7
Clinical atrophy 0 3 2
Table 8. Overview of neurophysiological data. Pathological ENeG values divided into septic 
(left) and non-septic (right) patients. 
Black boxes represent pathological values on day 4, 14 or 28; white boxes within normal 
ranges all three days. Med: median; per: peroneal. 
Table 7. Temporal changes in CIPNM, its components and clinical data. 
M/A: myosin/actin ratio; n/a: not applicable; 
CIP: critical illness polyneuropathy; 
CIM: critical illness myopathy; 
CIPNM: critical illness polyneuropathy and myopathy; 
ICU: intensive care unit.
Results
Patient 
(septic) 
Pathologic 
CMAP  
med+per 
nerve 
Pathologic 
SNAP 
median 
nerve 
Patient 
(non-septic) 
Pathologic 
CMAP 
med+per 
nerve 
Pathologic 
SNAP  
median 
nerve 
1   5   
2   6   
3   8   
4   9   
7   10   
!
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Paper III 
Neurophysiological changes
No significant change in motor nerve CV was 
observed. CMAP was significantly reduced in 
all intervention groups between day 1 and 5 
(figure 7).  
Single-fibre muscle force 
Muscle specific force (maximum muscle force 
normalised to cross-sectional area, CSA) was 
significantly decreased for the corticosteroid, 
sepsis and ALL groups (figure 8). 
Figure 7. CMAP for the tibialis anterior muscle. Left bar: day 1, right 
bar: day 5. Asterisk denotes a statistical significance between day 1 and 
5 (p<0.05). ALL: MV+sepsis+CS+NMBA.
 
Figure 8. Single muscle fibre size and contractile function. Values for day 1 (left, brighter bars) and 
day 5 (right, darker bars). The asterisk denotes a statistically significant difference between days 1 
and 5 (p<0.05).
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Paper IV 
Muscle biopsies and mitochondrial analyses
Light microscopy did not show any 
differences between the study groups; there 
were no signs of fibre atrophy. The myosin to 
actin ratio did not differ significantly between 
the MV and the ALL group.  
In intercostal muscle, no differences were 
seen between the different intervention 
groups. For the biceps femoris and diaphragm 
muscles, complex I was decreased between 
the ALL and CoS groups compared with the 
control and MV groups (figures 9 and 10). If 
the ALL and CoS groups are combined, the 
changes were statistically significant versus 
controls (figure 11).
Figure 9. Mitochondrial enzyme changes at day 
5 between intervention groups for the diaphragm 
muscle. ALL: MV+CoS+NMBA+Endotoxin.
Figure 10. Mitochondrial enzyme changes at day 5 
between intervention groups for the biceps femoris 
muscle. ALL: MV+CoS+NMBA+Endotoxin.
Figure 11. Mitochondrial changes in combined intervention groups.  
ALL: MV+CoS+NMBA+Endotoxin. p<0.05 for combined groups vs. controls.
Results
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discussion 
Why do some patients treated in the ICU 
become so weak that they can not move their 
extremities and are completely bedridden, while 
other patients with seemingly the same type of 
situation and disease are not affected? What can 
we learn from standard neurophysiological and 
bedside evaluation of neuromuscular function 
in the critical care setting, and can we obtain 
additional information from muscle samples? 
If the muscle weakness were a simple matter 
of inactivity, would we not see these symptoms 
in almost all patients? Obviously, this is not 
the case. Moreover, if sepsis were the single 
factor underlying CIPNM, one would expect 
the incidence to mirror that of sepsis in the 
critically ill. However, this is obviously not 
the case either. Hence, other factors may be 
anticipated to serve as the initiators of this 
condition.
The CIPNM diagnosis is challenging and 
is usually based on a neurophysiological 
examination fraught with difficulties in the 
ICU. The neurophysiological examination 
must often take place in a limited patient space 
which is occupied by necessary technical 
equipment, creating a possible risk of electrical 
disturbances. Wound dressings, casts and 
other obstacles to successful investigation 
are not uncommon, and the critically ill 
patient is often confined to certain positions, 
to avoid unwanted circulatory or respiratory 
effects if moved. Finally, ensuring that both 
patient and examiner are undisturbed during 
the whole examination can be a challenge. 
CIP and CIM often coexist, but even if they 
occur in isolation, the diagnosis can be difficult 
to make: even a pure myopathy cannot be 
distinguished from a pure axonal neuropathy 
if the patient cannot activate muscles 
voluntarily. In response to these problems, a 
shorter neurophysiological examination has 
been suggested to identify CIPNM patients, 
but includes the reservation that ”these 
[patients] should have full neurological and 
electrophysiological evaluations” 70. A muscle 
biopsy might therefore be necessary to diagnose 
a myopathy. That said, there are descriptions 
of direct muscle stimulation (dmCMAP) 
examination, differentiating CIP and CIM, which 
could be valuable 71. However, the technique is 
technically demanding and might be even more 
uncomfortable for the patient than obtaining a 
muscle biopsy under local anaesthesia. Patients 
relate discouraging stories of their traumatic 
perception of care-related procedures carried 
out during an often clouded mental state 72. 
In view of this, we showed in paper I a rapid, 
alternative method of diagnosing CIM. 
 
Using muscle samples followed by 
electrophoresis, like the SDS-PAGE, is an 
established method of calculating protein 
content, including myosin, actin and the 
myosin/actin ratio. The method described 
in paper I uses a horizontal, ultra-thin gel, 
working faster than other gels, with a between-
gel variation of 5%. This could therefore be 
an attractive alternative to current clinical 
diagnostic tools. An obvious limitation is the 
method being invasive.
Studies show that CIPNM is common, with 
a prevalence often exceeding 50% 29, 73-74. In 
prospective prevalence studies, the timing of 
serial examinations has varied. deLetter et al45 
used an interval between investigations (4, 
11 and 25 days after the start of mechanical 
ventilation) similar to that used in paper II (4, 
14 and 28 days) – and showed that SIRS was 
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present in 48%, and CIPNM in 33% of the 
patients. 
 
Here (paper II), we prospectively included 
ICU patients who had been mechanically 
ventilated for 72 hours. Although a small 
number of patients were included, CIPNM was diagnosed in patients with sepsis during their ICU stay, and represented 50% of the study population. Importantly, the septic patients all received corticosteroids, so separating sepsis from corticosteroid administration was not possible. At day 4, all CIPNM patients had an isolated CIP, and 
at day 14, two of these also had a myopathy. 
At day 28, only one patient from day 4 still 
had an isolated CIP, and one patient had a 
combination of CIP and CIM. From these data, 
we suggest the diagnosis of CIP, CIM and/
or CIPNM is dependent upon the time of the 
examination during the ICU course, owing 
to the variable temporal pattern. In order for 
results from clinical studies to be reproducible, 
or at least fairly comparable, examination 
dates should therefore be standardised. On the 
other hand, specific dates cannot be arbitrarily 
chosen for clinical diagnosis. Many factors 
can contribute to the patient being unable to 
comprehend commands for voluntary muscle 
activation, and a large number of ICU patients 
seem to meet neurophysiological criteria 
for CIPNM early in the ICU course. Our 
findings do not warrant a recommendation 
for performing prospective, comprehensive 
neurophysiological examinations for all 
ICU patients. Considering the examination 
difficulties described previously, an initial 
exam as a “starting point” at ICU admission 
does not seem feasible either.
Having completed a methodological study and 
an attempt to examine CIPNM prevalence, 
our attention turned to possible risk factors 
and mechanisms. In the literature, several 
factors have been suggested as being involved 
in the development of CIPNM, such as 
inactivity, NMBAs, corticosteroids and sepsis. 
In designing our study, no previous studies 
suggested how to construct intervention 
groups, nor how large the expected changes 
in neurophysiological examinations and 
mitochondrial enzyme analyses were likely 
to be. For 5-day studies, not only are there 
substantial costs for materials, but significant 
time and other resources are needed to make the 
study possible. Also, ethical standards dictate 
that the number of animals used for studies be 
kept to a minimum. We were therefore aware 
that the small size of the study groups was a 
limitation, but hoped that the study would 
provide initial information, and possibly enable 
us to use data from these studies to be able to 
design future studies with correctly powered 
groups, should these be warranted. In spite of 
this, there were significant changes.
From the earliest cases describing near paralysis 
related to intensive care 23-24, there is substantial 
evidence that high-dose cortisone is related to 
CIPNM development, but studies have so far 
been inconclusive. In paper II, we could not 
distinguish between sepsis and corticosteroids 
as risk factors, since patients with CIPNM 
had both sepsis and received corticosteroids. 
Therefore we wanted to include a CoS 
intervention group as a separate challenge 
in our animal model. We chose the dose of 
50 mg, which corresponds to approximately 
2 mg/kg, three times daily.  This dose might 
seem high, but patients in study II received 
up to 100 mg three times daily. Therefore, we 
judged that the study dosage was justified. 
 
In examining possible mechanisms for muscle 
changes, we examined neurophysiological 
variables, muscle fibre specific force and 
mitochondrial enzyme changes. Both for 
muscle fibre specific force (paper III) and 
mitochondrial enzyme I decrease (paper 
IV), there was a significant change in the 
intervention groups receiving CoS. These 
findings indirectly imply that corticosteroids 
have a deleterious effect on muscle function. 
The Cochrane Collaboration published a report 
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in 2009 75, stating that no significant effect of 
corticosteroids was seen on the development 
of CIP/CIM. The one study 76 that this was 
based on included 180 ARDS patients, with 
only 93 having prospective CIP/CIM data. 
In this study, the authors stated they did not 
systematically assess nerve conduction or 
muscle function.  Interestingly, there were 
nine reports of severe adverse events related 
to neuro/myopathy and all nine patients were 
treated with methylprednisolone. In contrast 
to the conclusions drawn by The Cochrane 
Collaboration, the authors wrote ”methyl-
prednisolone did not increase infectious 
complications but may have increased the 
risk of neuromyopathy associated with critical 
illness”. 
It has also been shown earlier that sepsis as well 
as corticosteroid treatment are associated with 
increased circulating levels of glucocorticoids55, 
which are known to worsen the effect of 
immobilisation on muscle function77. Reactive 
oxygen species can increase due to higher 
levels of glucocorticoids78, which may lead to 
changes in contractile proteins79. Many different 
mediators are involved intracellulary56, 80, 
which can decrease protein synthesis as well as 
increased breakdown56, 80-81. Hence, these results 
combined with our present findings suggest a 
role for corticosteroids in the development of 
impaired nerve/muscle function in the critically 
ill.
Muscle contraction has earlier been shown to be 
pathologic in ICU patients with CIM15, 82. The 
neurophysiological criteria for CIPNM do not 
include assessment of muscle force, but need 
an additional clinical evaluation to evaluate 
muscular weakness which might then complete 
the diagnosis. In paper III, we wanted to examine 
neurophysiological findings together with 
muscle force experimentally, in intervention 
groups combining pharmacological agents with 
immobilisation and mechanical ventilation in 
respect to acquired myopathy. 
In paper III, the motor nerve conduction 
velocity did not change significantly in any 
of the intervention groups between days 1 
and 5, making myelin loss seem unlikely. The 
CMAP decreased significantly in all groups, 
with the largest decrease in the ALL group. 
In this context, inactivity and mechanical 
ventilation alone seem sufficient to induce 
changes consistent with the neurophysiological 
criteria for CIPNM. The CMAP decrease 
is considered to be due to defective sodium 
channel regulation which causes a decrease in 
muscle membrane excitability83-85. The single 
muscle fibre maximum force was normalised to 
CSA, and was found to decrease significantly 
in the intervention groups with either CoS or 
endotoxin, and in the ALL group. This was 
also regardless of MHC isoforms I, IIa or IIx. 
Nor was a difference in maximum shortening 
velocity seen.  The myosin/actin ratio was 
normal. The contractile changes were thus 
seen before any myosin loss or fibre atrophy, 
suggesting that sepsis and CoS could induce an 
early loss of contractile proteins.
In paper II, we noted a difference between the 
patients with and without sepsis with regard to 
mitochondrial citrate synthase and mSOD.  A 
somewhat unexpected finding was the lack of 
change, in either direction, in complexes I and 
IV, which could of course be due to the small 
number of patients. 
Three of the septic/CIPNM patients (and none 
of the non-septic) had pathological myosin to 
actin ratios. Their Complex IV was unchanged, 
but Complex I was lower than that of the other 
patients (figure 12). This is without statistical 
significance, but the finding is interesting in 
the light of  our findings in paper IV.
Morphologic changes seen in mitochondria 
after sepsis have been documented earlier 86 
which suggest impaired function. There is 
currently a controversy regarding the impact 
of sepsis on mitochondrial function. Recent 
reports have shown divergent results (i.e. both 
increased and decreased function), but with 
longer duration studies there seems to be an 
Discussion
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initial increase in activity that later during the 
course of sepsis turns into decreased activity 87. 
Various theories behind mitochondrial 
dysfunction have been put forward, such as 
impaired microcirculation resulting in an 
oxygen shortage to the cell and mitochondrion88. 
However, studies have shown that oxygen 
delivery in multiple organ failure is within 
normal limits. For instance, intestinal oxygen 
consumption remained unchanged as impaired 
oxidative phosphorylation occurred 89. Thus, 
although the time course of mitochondrial 
impairment is still only partly understood, 
overall mitochondrial dysfunction is well 
documented in sepsis. 
 
Considering that mitochondria are the 
body’s energy producer, that skeletal muscle 
contains vast amounts of mitochondria, that 
mitochondria are known to be affected in 
sepsis and that a large proportion of critically 
ill patients become weak, the mental leap 
to examining mitochondrial function in this 
animal model is not that great.
The results from study IV show a decreased 
complex I activity in the animals receiving 
corticosteroids, or belonging to the ALL group. 
The decrease was seen in the biceps femoris 
and diaphragm muscles, but not in intercostal 
muscle.
However, there was no change in myosin/
actin ratio. As commented on paper III, 
there seem to be early changes that are not 
reflected by decreased myosin content. These 
early contractile changes might therefore be 
associated with a decreased mitochondrial 
complex I activity.
In a study by Brealey et al 90, decreased 
mitochondrial function in skeletal muscle was 
associated with septic shock, and markers 
of oxidative stress correlated with Complex 
I decrease. Carré et al 91 likewise showed 
mitochondrial dysfunction in critically ill 
patients, with respiratory protein subunits 
depleted to a greater extent in non-surviving 
patients. The authors suggested that survival 
was associated with mitochondrial biogenesis 
activation early in the course of disease and that 
failure to activate this impaired recovery, hoping 
for new treatments to support biogenesis92.
The studies included in this thesis did not 
examine nutrition as a factor in CIPNM, 
but obviously a catabolic patient with poor 
nutritional status is not well equipped to 
resist muscular weakness. In the Cochrane 
report on CIP/CIM 75 the authors stated that 
intensive insulin therapy reduced CIP/CIM 
(one heterogeneous group) incidence.  The 
”conventional insulin therapy group” described 
in the Cochrane report was treated with insulin 
when blood glucose levels were over 215 mg/
dL and stopped when below 180 mg/dL 48, 93. 
In our practice, we believe these are very high 
glucose limits. The ”intensive insulin therapy 
Figure 12. Mitochondrial complexes I and IV in 
different patient groups from paper II. M/A: group 
where myosin to actin ratio is less than 1.0.
39
group” we consider to have clinically normal 
limits. We did not see any significant difference 
in blood glucose level between the sepsis and 
the non-sepsis groups. We believe the reason 
for this is that none of the patients reached 
extremely high values other than occasionally 
in either the sepsis or the non-sepsis groups.
There are several different animal models 
for sepsis. Our aim was to simulate the ICU 
situation as closely as possible for up to 5 
days. For this situation, the small animal 
gold standard model - the caecal ligation and 
puncture model - was judged to be unsuitable. 
Although the sepsis resemblance to endotoxin 
is debated, pigs are sensitive to endotoxin just 
like other primates but unlike rodents 94. With 
regard to the potency of E.coli lipoprotein 
saccharide (LPS) infusion, the range of 
endotoxin in one mg of LPS can vary greatly 
between both strains and batches, and a more 
accurate way of describing the amount of LPS 
is to list the dosage in endotoxin units . mg-1 
(EU . mg-1). Since this is only occasionally 
mentioned in published articles, we had little 
prior information on which dose to use for these 
prolonged experiments. Therefore our endpoint 
was the clinical septic reaction instead of a 
specific dose. To avoid differences in potency 
between LPS batches, the same LPS batch was 
used for all animals.
 
We employed a porcine sepsis model due to 
the many similarities with human cardiovas-
cular physiology, endotoxin sensitivity and 
antigenicity 95-97. Animal size allows exten-
sive instrumentation for serial and continuous 
haemodynamic monitoring. To our knowledge, 
there are few reports of prolonged sepsis mod-
els which have been maintained for as long as 
five days. Models of porcine sepsis have used 
endotoxin infusion, bacterial infusion, and 
peritonitis as infection stimuli 98 . Earlier por-
cine endotoxin infusion protocols have ranged 
from 0.25 ug . kg-1 . hr-1 for 3 hours up to 400 
ug . kg-1 . hr-1 over 1.5 hours 99-103. In this study 
the endotoxin dose was titrated to effect, an 
approach previously described 104-105 and which 
we found physiologically attractive and man-
ageable over a five day experimental course. 
The endotoxin average dose of 8 ug-1 . kg-1 . hr-1 
enabled the animals to survive a 5-day experi-
ment after encountering a severe septic shock 
on day 1, that was defined by systemic hypo-
tension and pulmonary hypertension.
Even when choosing a suitable animal model of 
ICU care that corresponds to interventions used 
for humans, there are limitations. First of all, we 
used young animals that do not correspond to 
the human age in our studies (56 years in paper 
I, 54 years in paper II). We only used female 
pigs and we cannot exclude the possibility of 
hormonal interference with our results. Finally, 
the concept of using otherwise healthy animals 
may be questioned, since patients in the clinical 
setting often have additional co-morbidities.
Since the earliest reports of critical illness 
polyneuropathy and myopathy, sepsis / SIRS 
and various medications have been suspected 
of contributing to the neuromuscular changes 
observed42-48.  As a result, many institutions 
have revised routines for deep sedation during 
ICU care, opting instead for “lighter” sedation 
without paralysis, resulting in more conscious 
patients 106-107. Lighter sedation, together with 
more active attempts at patient mobilisation, 
are thought to lead to shorter ICU stays and 
reduced risk of CIPNM 108-109. As critical illness 
hampers patient mobilization in the ICU, it 
is very difficult to use retrospective data to 
separate and quantify how different aspects of 
ICU care contributed to complications such as 
CIPNM.  Our data suggests, for example, that 
inactivity itself may contribute most to CIPNM. 
In addition to separate, unique pathologic 
mechanisms, an association between sepsis 
and CIPNM might also reflect the fact that 
sepsis prolongs ICU stay and thereby inhibits 
mobilisation. It may be suggested that sepsis is 
a surrogate marker for inactivity and delayed 
mobilisation. In support of this assertion, the 
duration of mechanical ventilation has been 
Discussion
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associated with CIPNM in three studies, one 
of which included a multivariate analysis of 
independent risk factors 29, 44.
If a patient presents with symptoms of 
symmetrical extremity weakness, or signs 
of difficulty in weaning from mechanical 
ventilation, including having to change from 
non-invasive110 to mechanical ventilation 
for no obvious reason, a thorough CIPNM 
investigation should be initiated. This should 
include EMG in addition to ENeG  if the patient 
is cooperative, otherwise a muscle biopsy 
might be necessary. If there is reason to believe 
that the patient will encounter difficulties 
in rehabilitation after the ICU as a result of 
muscular weakness, the CIPNM diagnosis is 
also important. Not only is it important for 
the patient and relatives to comprehend why 
there is a pronounced muscle weakness 111, 
but also for future caregivers to evaluate the 
result of rehabilitation correctly and to adjust 
physiotherapy and training more closely to the 
individual patient’s needs. 
After World War II, there was already an insight 
into the importance of rehabilitation. Not only 
was the personal benefit of rehabilitation 
appreciated, but also the spectacular 
economical gain for society 112. In 1949, when 
Rusk published this study, and for many years 
after, rehabilitation was considered ”the third 
phase of medicine”, applied after diagnosis 
and treatment. This view has now changed. 
Rehabilitation is so important that it should start 
as soon as the patient is sufficiently stable 108. 
There is no doubt that physiotherapy is 
important in rehabilitation after ICU care 113-114 
but there is a lack of sound scientific evidence 
as to which treatments are most effective, and 
this also holds true for CIPNM rehabilitation. 
In the NICE (National Institute for Health 
and Clinical Excellence) clinical guidelines 
entitled ”rehabilitation after critical illness”, it 
is stated that no evidence-based rehabilitation 
guideline for the management of critical 
care-associated morbidity exists. No clinical 
practice specifically targeted at physiotherapy 
and ”muscle weakness” is suggested in the 
report 115.
Although physiotherapy probably does not 
enhance nerve reinnervation, a patient with 
polyneuropathy may experience problems both 
with balance and proprioception, and needs 
rehabilitation that targets these problems. If 
a pure myopathy exists, enhanced strength or 
endurance training might stimulate mRNA 116-117, 
thereby producing more myosin or other 
contractile proteins 118, which possibly could 
accelerate rehabilitation. If the early changes 
described in paper III and IV do occur, they 
probably do so before the patient has been 
diagnosed with CIPNM. More research into 
pharmacological intervention needs to be done 
to reverse these changes. As mentioned in the 
introduction, there are many more functions to 
the skeletal muscle fibre than being just a support 
and force generator. Intervening in highly 
specific pathways to enhance mitochondrial 
function in critical illness may involve many 
setbacks before we understand sufficiently. 
There have been earlier interventions with both 
growth hormone and magnesium 119-121 which 
did not show benefit, and treatment with growth 
hormone actually increased the mortality 121. 
Until further research has revealed more facts 
about muscular changes in critical illness, the 
usual ICU rule ”make it normal” may apply. 
An individually targeted rehabilitation plan 
that includes physiotherapy for an ICU patient 
who has been correctly diagnosed with CIPNM 
is a good start.
Quoting Rusk on rehabilitation, in 1949 112 :  
”The …. physician who fails to see that those 
patients under his care receive the full benefits 
41
of modern methods of medical rehabilitation 
and retraining, is in the same category as 
the physician who still persists in using 
dietary restriction alone in the management 
Discussion
of diabetes, when insulin is available, for 
medical care is not complete until the patient 
has been trained to live and work with what 
he has left”.
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concLusions
I. For rapid diagnosis, horizontal SDS-pore PAGE is suggested as a diagnostic tool to de-
termine the myosin/actin ratio in patients with suspected critical illness myopathy. 
II. CIPNM can be seen early in the ICU course and seems to be more likely to occur in 
patients with sepsis and corticosteroid treatment. The temporal pattern of CIPNM varies 
and does not seem to predict the clinical course. 
III. Immobilisation appears to be a key element triggering the lowering of the CMAP ampli-
tude. Sepsis and/or corticosteroid treatment decreased the specific force generation at the 
single muscle fibre level, independent of muscle fibre type. 
IV. In an experimental ICU model, inactivity does not seem to affect mitochondrial function. 
During mechanical ventilation, interventions with either corticosteroids or endotoxin, or 
the combination of endotoxemia, corticosteroids and NMBA, decrease Complex I acti-
vity in both respiratory and non-respiratory muscle.
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This is not the beginning. It´s not even the end of the beginning. It´s the end.
